Last reviewed · How we verify
Lyrica (low dose)
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), Partial-onset seizures (adjunctive therapy), Fibromyalgia.
At a glance
| Generic name | Lyrica (low dose) |
|---|---|
| Sponsor | KunWha Pharmaceutical Co., Ltd. |
| Drug class | Gabapentinoid; anticonvulsant; analgesic |
| Target | Voltage-gated calcium channel alpha-2-delta subunit |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management |
| Phase | Phase 3 |
Mechanism of action
By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, noradrenaline, and substance P. This modulation of neurotransmitter release dampens neuronal hyperexcitability, making it effective for neuropathic pain and seizure disorders. The low-dose formulation maintains the same mechanism but at reduced systemic exposure.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)
- Partial-onset seizures (adjunctive therapy)
- Fibromyalgia
- Generalized anxiety disorder
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial (NA)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
- Use of Driving Tests to Evaluate Patient Performance on Oral Opioids
- Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) (PHASE2)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)
- Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain (PHASE3)
- Sleep and Neuropathic Pain - Intervention Study on Pregabalin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lyrica (low dose) CI brief — competitive landscape report
- Lyrica (low dose) updates RSS · CI watch RSS
- KunWha Pharmaceutical Co., Ltd. portfolio CI